CLL/SLL

Sequoia trial: Which subset of patients with CLL/SLL benefits the most from zanubritinib treatment?

L: English

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. We asked about the results of the Sequoia trial and which subset of patients with CLL/SLL benefits the most from zanubritinib treatment?

Constantine Tam discusses the results of the trial investigating efficacy and safety of zanabrutinib, a small molecule BTK inhibitor, in patients with 17p deletion CLL, unsuitable for chemotherapy.

Was this article informative? Thank you for your feedback!
100% of people found this article informative